Vanishpoint and UNI are two very different beasts. UNI management know that the prefilled syringes they have created, specifically designed for integration with pharma manufacturing, is the future and is a very smart and commercial way for such a company to actually make it in the industry and become highly profitable.
Your constant pointing to VP and their products and yet not acknowledging the opportunity created with the prefill for UNI is suspect to me, especially for someone who says they are trying to point out everything to investors so they can make informed decisions.
Once again I'll say that management have said that the clinical range is not their main focuss and that the full range would be needed to make any headway here, they are focussed on the prefill as it is the company making opportunity. The production line for the 1ml was more or less "proof of concept" for management to know it works and can be replicated easily.
Pointing out companies that don't compete in the prefilled arena is a useless exercise imo.
Add to My Watchlist
What is My Watchlist?
